论文部分内容阅读
目的:评价脂微球脂微球前列腺素E1与甲钴胺联合应用治疗糖尿病周围神经病变的疗效与安全性。方法:计算机检索CNKI数据库,收集以脂微球脂微球前列腺素E1与甲钴胺联合应用为干预措施治疗糖尿病周围神经病变的随机对照试验研究。对纳入的研究文献进行方法学质量评价,提取有效数据进行Meta分析。结果:共纳入11个随机对照试验研究,共1013例糖尿病周围神经病变患者。试验组为基础治疗加脂微球前列腺素E1与甲钴胺联合应用,对照组为基础治疗或基础治疗加B族维生素。Meta分析结果显示,试验组在改善糖尿病周围神经病变患者的临床症状的有效率方面优于对照组(P<0.01)。结论:脂微球前列腺素E1与甲钴胺联合应用对糖尿病周围神经病变患者的临床症状有改善作用。因纳入文献的试验方法学质量较低,仍需开展科学规范、高质量、大样本、长期随访的随机对照研究。
OBJECTIVE: To evaluate the efficacy and safety of combination of prostaglandin E1 with mecobalamin in the treatment of diabetic peripheral neuropathy. Methods: The CNKI database was searched by computer. A randomized controlled trial was conducted to treat peripheral neuropathy of diabetes mellitus with intervention of lipid microsphere liposomes prostaglandin E1 and mecobalamin. Methodological quality evaluation of the included research literature, extraction of valid data for meta-analysis. Results: A total of 11 randomized controlled trials involving 1013 patients with diabetic peripheral neuropathy were included. Experimental group based on the treatment of lipid-loaded microspheres prostaglandin E1 and mecobalamin combination, the control group as the basic treatment or basic treatment plus B vitamins. Meta-analysis showed that the experimental group was better than the control group in improving the clinical symptoms of patients with diabetic peripheral neuropathy (P <0.01). Conclusion: The combination of lipid microsphere prostaglandin E1 and mecobalamin can improve the clinical symptoms of patients with diabetic peripheral neuropathy. Due to the low quality of the experimental methodologies included in the literature, randomized, controlled trials of scientific norms, high quality, large samples and long-term follow-up are still required.